7-chloro-8-methyl-2-pyridin-3-ylquinoline-4-carboxylic acid, 95.0%, 5g

1-(2-Methyl-3-(trifluoromethyl)phenyl)ethanamine hydrochloride, 98%, 250mg

5-Phenoxyvaleric Acid>98.0%(T)1g

E-Plan phase EPLPHi S100x/1.25 oil immersion infinity corrected IOS objective. Working distance 0.36 mm

8-Bromo-1-naphthaldehyde, 97%, 1g

8-methoxy-4-quinolinamine, 95.0%, 1g

4-(4-Bromophenoxy)tetrahydro-2H-pyran, 95.0%, 25g

1-Benzenesulfonyl-1 H -indole-3-carbaldehyde, 95.0%, 1g

3,5-Dibromo-2-iodobenzotrifluoride, 97%, 5g

tert-Butyl 4-(ethylamino)piperidine-1-carboxylate, 95.0%, 5g

3-methyl-2,4-dihydro-1,2-benzoxazol-4-one, 96%, 1g

7-Phenyl-pteridin-4-ol, 95.0%, 250mg

5-Bromo-6-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione, 95+%, 250mg